Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,216 across all filing types
Latest filing 2023-02-28 Earnings Release
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 28, 2023, by Pacira BioSciences, Inc. It announces the issuance of a press release with financial results for the fourth quarter and full year ended December 31, 2022. The document itself does not contain the financial results but furnishes the press release as an exhibit. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not deemed filed for certain regulatory purposes. The document length is 3425 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, a short document announcing the release of financial results and attaching a press release is classified as an Earnings Release (ER).
2023-02-28 English
SC 13G/A
Major Shareholding Notification
2023-02-14 English
SCHEDULE 13G/A
Major Shareholding Notification
2023-02-09 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-23 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and includes a press release with preliminary unaudited revenue figures for a recent period. The document does not contain full financial statements or detailed financial analysis but rather a brief announcement of preliminary financial results. The length is 3421 characters, which is relatively short and consistent with a current report or earnings release announcement. Given that it announces preliminary financial results and includes a press release, this fits the definition of an Earnings Release (ER) rather than a full Annual or Interim Report. Therefore, the appropriate classification is Earnings Release (ER).
2023-01-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.